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ABSTRACT
 A new light has recently been shed on palliative care, especially, on its multidisci-
plinary approach developed to improve the Quality of life of seriously ill patients and their 
families. However, palliative care is still often mistakenly referred to as an end-of-life care and 
wrongly interchanged with hospice care. Nephropathic patients usually present a decrease in 
expectancy and Quality of life and may benefit from palliative care as opposed to hospice care. 
Palliative care requires a tight collaboration among different health care professionals, patients 
and their families, to share diagnosis, prognosis, realistic goals of treatment and therapeutic 
decisions. Several approaches may be attempted to improve the Quality of life of chronic neph-
ropathic patients, such as palliative dialysis, conservative management and peritoneal dialysis. 
For example, personalized goals and a wider concept of adequacy of extracorporeal treatment 
are the bases of palliative dialysis. In specific subgroups of frail patients, the pharmacological 
conservative management could be more appropriate than extracorporeal treatment, as the for-
mer reduces the burdens derived from invasive procedures. Finally, peritoneal dialysis could 
be an important option for frail patients to avoid an aggressive extracorporeal treatment while 
maintaining a gentle solute and fluid control. However, only limited evidences are available 
on palliative and hospice care performed on patients with Acute Kidney Injury (AKI). Herein, 
the main variables affecting the medical decision-making on palliative care in nephropathic 
patients are described, and the different approaches available to improve quality of palliative 
care during Chronic and Acute Kidney Injury are analyzed.
KEYWORDS: Palliative care; Hospice care; Chronic Kidney Disease; End-Stage Renal Disease; 
Acute Kidney Injury; Renal Replacement Therapy.
 
ABBREVIATIONS: AKI: Acute kidney Injury; CKD: Chronic Kidney Disease; ESRD: End-
Stage Renal Disease; RRT: Renal Replacement Therapy; ERA-EDTA: European Renal Associ-
ation-European Dialysis and Transplant Association; MCM: Maximum Conservative Manage-
ment; PD: Peritoneal Dialysis; ICU: Intensive Care Unit.
INTRODUCTION
 Palliative care has recently been reconsidered as a multidisciplinary approach to care 
which has been developed to support clinicians in the management of patients with serious 
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illness.1 This innovative perspective is aimed to improve the 
Quality of life of patients and their families through a multidi-
mensional analysis involving: 1) identification and management 
of patients’ physical, psychological and spiritual symptoms; 2) 
evaluation of patients’ clinical condition and prognosis to estab-
lish realistic and appropriate treatment goals; 3) arrangement of 
individualized therapeutic plans according to patients’ wishes; 
4) attention to families’ needs and 5) support for health care pro-
viders.1 
 Currently, the specialty palliative care is mainly offered 
in patients within hospices or hospitals only when life-prolong-
ing treatment has failed;2 as a consequence, most of health care 
professionals perceive palliative care as a synonymous of End-
of-life care.2 However, limiting palliative care only to these situ-
ations may exclude the majority of serious conditions, such as 
advanced cancer or end-stage organ dysfunction, which severely 
affect patients’ physical and psychological symptoms.2,3 For 
these reasons, palliative care should be provided together with 
life-sustaining treatments and considered as an integral compo-
nent of comprehensive therapy for critical and non-critical care 
patients. Therefore, palliative care is neither a mutually exclu-
sive alternative to intensive care, nor a sequel to failed attempts 
with life-prolonging care,1 in fact, according to the definition de-
veloped by the Center to Advance Palliative Care and the Ameri-
can Cancer Society, “Palliative care is appropriate at any age, at 
any stage in a serious illness, and can be provided together with 
curative treatment”.2 On the other hand, hospice care is strongly 
recommended for patients who have a physician-estimated life 
expectancy of 6 months or less and who are undergoing restor-
ative treatments and foregoing curative therapy.2 
 Despite the improvements in therapeutic options, pa-
tients with AKI as well as those with Chronic Kidney Disease 
(CKD), especially those with End-Stage Renal Disease (ESRD), 
have a shorter life expectancy compared to patients without 
nephropathies. Extracorporeal replacement therapies may in-
crease survival rates of these patients; however, for a specific 
subgroup of acute critically ill patients, these procedures are of-
ten unable to improve outcomes and prolong the physiological 
process of death, worsening the quality of the End-of-life stage 
of these patients.
 Several clinical trials have shown the benefits derived 
from the early application of palliative care in subgroups of seri-
ously ill patients, such as those with advanced cancer,4 multiple 
sclerosis5  or congestive heart failure.6,7 However, the provision 
of palliative care to nephropathic patients with CKD or AKI is 
heterogeneous across different countries and often mistakenly 
identified with hospice care. Currently, the use of palliative care 
in the nephrophatic population is inadequate; it is recognized in 
the UK, USA, Italy and Canada mainly for ESRD patients8-12 and 
is usually limited to the last phase of life. Finally, an adequate 
approach for palliative care is still largely lacking for patients 
with AKI.
 The aim of this review is to describe the main vari-
ables affecting the medical decision-making on palliative care 
in nephropathic patients and to analyze the different approaches 
to improve quality of palliative care during Chronic and Acute 
Kidney Injury. 
PALLIATIVE CARE FOR CKD PATIENTS
 Demand for dialysis is constantly increasing all over 
the world, especially in the elderly population.13,14 As clearly 
demonstrated by the European Renal Association-European Di-
alysis and Transplant Association (ERA-EDTA), the European 
incidence of ESRD requiring dialysis procedures among patients 
aged > 65 years increased from 22% in 1980 to 55% in 2005.15 
The recent technological advancements observed with the Renal 
Replacement Therapy (RRT) have increased feasibility of these 
techniques and have improved survival for a large number of 
patients with ESRD. 
 Despite the increased survival, an annual mortality rate 
of about 23% has been reported for ESRD patients undergoing 
RRT16 which mainly depended on the high prevalence of other 
chronic comorbidities, such as diabetes, hypertension and car-
diovascular diseases.17 A reduction in the overall functional sta-
tus during the first 12 months after initiation of RRT has been 
reported for patients with CKD and, specifically, for a subgroup 
of nursing home residents.18 Finally, an increasing burden of so-
matic and psychological symptoms as well as a worsening of so-
cial conditions have been often observed among ESRD patients 
undergoing RRT.19 These symptoms, whose prevalence is com-
parable to those observed in cancer patients,20 severely affect the 
patient’s Quality of life.19 In these conditions, a high proportion 
of elderly patients regrets the decision to start dialysis and thus, 
after agreeing with caregivers, prefers a conservative manage-
ment for ESRD.21 
 Training, information and support for patients, their 
family and caregivers are pivotal for planning the management 
of care of ESRD patients. In particular, other therapeutic options 
such as, extracorporeal treatment, Peritoneal Dialysis (PD) or 
Conservative therapy should be discussed and comprehensively 
shared among patients, family and health care providers. Both 
for patients undergoing RRT and for those managed with con-
servative therapy, palliative medicine should be taken into con-
sideration in order to improve the Quality of life.
EXTRACORPOREAL RRT
 Extracorporeal therapy is the most utilized treatment to 
replace renal function in ESRD patients.22 Adequacy of extra-
corporeal treatment is often identified with the concept of solute 
clearance, which is usually quantified through Kt/V measure-
ment. However, the strong effort in treatment personalization 
has recently encouraged to carefully evaluating the specific tar-
get of therapy, which has to aim not only at the solute removal 
                                          PALLIATIVE MEDICINE AND HOSPICE CARE
Open Journal
http://dx.doi.org/10.17140/PMHCOJ-1-104
Palliat Med Hosp Care Open J
ISSN 2377-8393
Page 18
but rather at the improvement of the whole patient’s clinical pic-
ture. Although reasonable and attractive, this concept is still far 
from being applied in most dialysis centers in the daily clinical 
practice.
 Indeed, following analysis of data on treatment targets 
in CKD patients from 12 countries, the Dialysis Outcomes and 
Practice Patterns Study (DOPPS) showed no difference in dialy-
sis prescription across subgroups of patients with different clini-
cal requirements. For instance, the same treatment time, normal-
ized by body weight, was prescribed both for patients aged < 45 
years and frail elderly patients.23 Targeting the normalization of 
dry weight, Kt/V and serum phosphorus, may not be the primary 
treatment objective for all patients.15 Apart from these specific 
clinical issues, the concept of adequacy of RRT should also take 
into account the ability to achieve other treatment goals, such 
as the improvement of the Quality of life of patients and their 
families, the prevention and relief from suffering, the identifica-
tion and treatment of pain and other physical and psychosocial 
conditions. 
 In a recent paper, Romano and Palomba proposed the 
concept of palliative dialysis as a change in perspective for the 
treatment goals achievable by using either ultrafiltration or dialy-
sis alone, depending on the clinical objectives.15 In this scenario, 
an individualized RRT prescription overlaps with the require-
ment of palliative care and it may improve the physical, emotive 
and autonomy-related issues (Figure 1). 
 As such, the delivery of palliative care should be started 
not during the last moments of patients’ lives but, concomitantly 
with RRT.15 
 The quality of care given to the patients may be eval-
uated through the PEACE score: a simple tool addressing six 
domains on physical, emotive, autonomy-related symptoms; 
communication and completion of life issues; economic burden 
and religious beliefs.24 However, although this tool may be of 
help for clinicians, the most important factor to consider when 
making a clinical decision is the autonomy of the patient who 
faces ESRD and of the relatives who provide support.15 In par-
ticular, Parlevliet et al. showed that caregivers are often forced 
to change their routine and professional schedules, and 84% of 
them feel overburdened by the situation.20 
 Among the most frequent symptoms observed in ESRD 
patients, such as lack of energy, drowsiness, dry mouth, pain, sleep 
disturbance, restless legs, pruritus, dry skin and constipation,25 
dyspnea may be the most manageable with palliative dialysis.15 
Indeed, although other symptoms can be treated with medica-
tions, fluid overload and acidosis are rarely controlled in ESRD 
patients conservatively managed.15 
CONSERVATIVE MANAGEMENT
 Conservative management should be taken into account 
for patients who are not eligible for extracorporeal treatment or 
who refuse it. It is based on a pharmacological and behavioral 
approach used to prevent the major complications of ESRD, 
such as hydro-electrolytic unbalance, acid-base disorders, hy-
perazotemia and anemia. This option is usually limited to pa-
tients with severe comorbidities and geriatric conditions, such as 
dementia and frailty.15 
 Frailty, in particular, is a multidimensional construct 
reflecting the decline in health and organ function observed in 
elderly; it occurs in approximately 67% of dialysis patients.26 
Frailty is correlated with an increased risk for disability, hospi-
Figure 1: “Adequacy” of Extracorporeal treatment and the role of Palliative dialysis.
Graph of a chronic extracorporeal renal substitution for CKD patient (panel A) and graph of palliative dialysis for “CKD end-of-life” patient (panel B). Each graph takes into consider-
ation several variables differently affected by the treatments (0: the variable is minimally influenced; 10: the variable is strongly improved). 
The adequacy of the treatment may be identified by the area within the graph: during an ideal therapy, the inner area covers 100% of the graph. For a treatment to be “adequate”, 
other parameters than solute clearance or fluid balances should be considered for end of life patients; in this scenario, an individualized RRT prescription should improve the physi-
cal, emotive and autonomy-related issues.
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talization, institutionalization and death27 and it is clinically di-
agnosable through recognition of unintentional weight loss, slow 
walking speed, weakness, exhaustion and low level of physical 
activity.28 The use of conservative management is recommended 
in patients with this clinical picture.
 In line with this view, Maximum Conservative Man-
agement (MCM) is a European proposal based on a multidis-
ciplinary approach with nutritionists, social workers, psycholo-
gists and other health professionals aimed at improving the 
Quality of life of frailty patients with ESRD.29 Despite patients 
who received RRT showed a higher survival rate than those who 
received MCM, they had higher rates of hospitalization and in-
hospital death.30 
 Although necessitating the lowest institutionaliza-
tion requirement, the conservative management requires close 
monitoring and treatment adjustment by several professional 
figures in order to avoid treatment failure. In particular, a con-
stant sharing of achievable therapeutic goals should be encour-
aged between general practitioners or specialists on one side and 
patients and their families on the other. This procedure aims to 
reduce accesses in emergency department and thus invasive pro-
cedures and hospitalizations. Nevertheless, a multidisciplinary 
approach is required to limit patient’s symptoms and suffering 
from a home delivery palliative care system. 
PERITONEAL DIALYSIS 
 Another type of management available is Peritoneal 
Dialysis (PD); its use is suggested in frail patients as, in this 
specific subgroup of nephropathic patients, PD may offer ad-
vantages with respect to both extracorporeal RRT and conserva-
tive management. Indeed, hemodynamic instability and severe 
hypotension may affect extracorporeal RRT, further worsening 
frail patients’ clinical conditions. PD is considered a less inva-
sive treatment, which guarantees a slow, continuous dialysis and 
ultra filtration; it is usually more tolerated by patients and it may 
preserve better renal function, hence allowing a less restricted 
and more patient-friendly diet. As well as extracorporeal RRT, 
PD is able to compensate metabolic acidosis and fluid overload 
that may cause exacerbation of patients’ condition in conserva-
tive management. However, similarly to conservative therapy, 
PD may be managed through home care and occasionally sched-
uled ambulatory visits, making it an effective choice for patients 
requiring palliative or hospice care.31 
 In 2008 ERA-EDTA pointed out some criteria that may 
be used to recommend PD.32 In particular, clinical conditions that 
may be usually identified in frail patients, such as aging compli-
cations, severe Cardiac Disease or Peripheral Vascular Disease, 
have been recognized as potential indicators for PD prescription. 
However, ERA-EDTA also identified factors with which use of 
PD may be contraindicated; these factors include inadequate 
patient’s physical ability and lack of familiar or social support. 
In fact, the family involvement in the patient’s disease is more 
demanding in PD than in extracorporeal RRT and conservative 
management, considering that a technical training of the patient 
and/or caregiver to the peritoneal dialytic procedure is manda-
tory. 
 Despite a close cooperation between patients, their 
families, general practitioner, nurses and nephrologists is re-
quired, PD may guarantee a better quality of life, becoming thus 
the therapy of choice in a selected population requiring pallia-
tive or hospice care.
PALLIATIVE CARE FOR AKI PATIENTS
 AKI frequently occurs in critically ill patients in the 
Intensive Care Unit (ICU), with an estimated global preva-
lence of 36%-67%;33 it exhibits different etiologies and several 
pathophysiological mechanisms, and is correlated with a high 
mortality rate.34-38 
 Despite the poor prognosis associated with AKI, the 
concepts of palliative and hospice care are still underdeveloped 
for this specific subgroup of patients. Indeed, despite a grow-
ing interest in the literature on palliative care for critically ill 
patients in the ICU, only few papers have been focused on the 
withdrawal or withholding of invasive treatments in acute neph-
ropathic patients. In particular, a systematic search of the pub-
lished literature, performed on Pub Med using the following key 
words “Acute Kidney Injury” AND (“Palliative care” OR “Palli-
ative medicine”) and related MeSH terms, revealed 87 citations . 
Among them, 10 are specifically focused on “acute-on-chronic” 
conditions and advanced planning for ESRD patients; 32 couple 
AKI with other life-threatening conditions (e.g. heart failure or 
cancer) and underline the importance of palliative care medicine 
in these diseases; 39 are not relevant for this particular topic. 
Only 11 papers are specifically focused on palliative care for 
nephropathic patients with AKI. Among these, 5 reviews the eth-
ical issues.39-43 and 3 specifically describe the epidemiology and 
clinical factors associated with End-of-life in AKI patients.44-46 
 For these reasons, while palliative and hospice care 
management is globally applied in CKD patients, even general 
indications are still lacking in AKI patients. Nowadays, clini-
cians are often faced with critically ill patients who meet the 
criteria for initiating RRT, however, there are uncertainties on 
whether the patient would likely benefit from these procedures.47 
In fact, although critically ill patients are often subjected to ad-
vanced and invasive diagnostic and therapeutic interventions, 
mortality in the ICU remains very high.48 Therefore, in these 
settings, advanced life support procedures and systems, such as 
RRT, may only unreasonably postpone the time of death.49 
 Scarce literature is available to guide clinicians in 
the decision to discontinue RRT in patients who will no lon-
ger benefit.47 Although an evidence-based guideline on this use 
has been already produced by the Renal Physicians Association 
and the American Society of Nephrology,42 only a small number 
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of nephrologists and intensivists are aware of it.11 As a conse-
quence, clinical practice on withholding or withdrawal of RRT 
is variable and based primarily on the local institutional prac-
tice, physicians’ clinical judgment, available resources and local 
management.36,38,50-52 
 Several factors should be taken into consideration dur-
ing the decision-making process regarding the withholding or 
withdrawal of RRT in patients with AKI, including feasibility, 
survival prediction, renal functional recovery prediction and 
quality of life. 
 Clinical feasibility is certainly an important limiting 
factor. Although several patients’ clinical conditions (e.g., se-
vere hypotension) might negatively affect the technical feasi-
bility, new techniques such as continuous Renal Replacement 
Therapies have allowed performing RRT in the vast majority of 
patients.47 
 An adequate medical judgment and an informed patient 
and family consent cannot ignore survival prediction as an im-
portant factor to be considered when deciding to continue, with-
hold or withdraw RRT. Despite several organ dysfunction scor-
ing systems53 and outcome prediction models available to help 
clinicians identify severely ill patients, none of them actually 
provide physicians with enough information on the suitability of 
intensive care treatments for the individual patient.49 Short and 
long term mortality of critically ill patients who developed AKI 
and required RRT is globally high (46-75%).54 The Study to Un-
derstand Prognoses and Preferences for Outcomes and Risks of 
Treatments (SUPPORT), the largest prospective study investi-
gating survival in critically ill patients, has shown that the mean 
survival time in patients who required dialysis was of approxi-
mately 30 days and that only 27% of patients were alive after 5 
months.55 
 Prediction of renal functional recovery after AKI should 
be considered as another important factor in determining long-
term renal and non-renal outcomes56-59 in the decision-making 
process.47 
 The Quality of life of patients and their families may 
be severely affected if ESRD occurs and chronic extracorporeal 
RRT is required after an episode of AKI. However, long-term 
outcomes and Quality of Life of critically ill patients requiring 
RRT have been examined only in few studies.47 For instance, in 
the SUPPORT study, AKI patients who survived to the critically 
ill stage showed a median of one dependence in activities of dai-
ly living;55 however, different results are shown in the published 
literature.43,60,61 
 Unlike in CKD patients, in critically ill AKI patients 
the time frame window to discuss the decision to initiate or stop 
RRT is often unavailable. Therefore, not knowing the patient’s 
own wishes make the clinical judgment even harder,62 and hence 
pressure to make a decision builds up among family and the 
health care team.47 
 According to the Renal Physicians Association/Ameri-
can Society of Nephrology guidelines of shared decision making 
in dialysis, a time-limited trial of RRT could be considered for 
patients with uncertain prognosis.63 In particular, it may result 
useful when a disagreement in management occurs between 
physicians and nurses or patients’ families.47 End-points, goals 
and duration of this time-limited trial should be exactly defined 
in advance. In particular, specific criteria, their magnitude of 
change accepted as evidence for improvement and the time point 
of their evaluation should be established and agreed between 
physicians, nurses, patients and their families.47 Notably, the de-
cision making regarding the withholding or withdrawal of RRT 
in patients with AKI during a time-limited trial is an ongoing 
process: clinical outcomes as well as patients’ prognoses should 
be revaluated as needed.47 
 In all cases in which RRT is withheld or withdrawn, 
physician should provide adequate End-of-life comfort care 
through non-dialytic therapy even for critically ill patients in the 
ICU.64 For patients with a death prognosis, different approaches 
other than integrating palliative care with intensive care treat-
ment should be adopted. Indeed, in these conditions, palliative 
care may be replaced by hospice care.1 In patients with terminal 
prognosis, the strategies to ensure a good death often involve 
more than effective analgesia and, ideally, should aim at opti-
mizing comfort and dignity for the patient and at offering the 
opportunity of a close support from the family. Allowing pa-
tients to die in their own homes is a way of providing this.65 Un-
fortunately, many patients suffer prolonged dying in hospitals, 
receiving unwanted, expensive and invasive treatments which 
may cause additional discomforts, such as pain, dyspnea, thirst 
and anxiety.66 
 New developed technologies, such as wearable artifi-
cial kidney, should be taken into consideration for hospice care 
in nephropathic patients. Although this concept may be hardly 
applied in daily clinical practice, it may be potentially useful in 
home care management even for patients with AKI. This minia-
turized, wearable technology may allow the maintenance of me-
chanical support, mainly through continuous ultra filtration. By 
improving fluid overload and reducing dyspnea, the wearable 
artificial kidney may provide human basic needs in end-of-life 
care60 even, with adequate support, at patient home. 
CONCLUSIONS
 Palliative care is usually limited to seriously ill patients 
at the end-of-life phase and is often wrongly interchanged with 
hospice care. An earlier utilization of palliative care for all seri-
ously ill patients may improve the quality of life of the patients 
and their families. Nephropathic patients usually present a de-
crease in life expectancy and may benefit from palliative care. 
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Although limited to end stages of the renal disease, the concept 
of palliative care is still better defined for CKD than AKI pa-
tients. Indeed, several therapeutic strategies may be attempted 
to improve Quality of life of chronic nephropathic patients, such 
as palliative dialysis, conservative management and PD. All 
these approaches require a tight collaboration between different 
healthcare professional figures, patients and their families. Prog-
nosis, realistic treatment goals and therapeutic decisions should 
be shared among all subjects involved in the management of 
CKD. On the other hand, poor literature data are available on 
the effects of palliative and hospice care in patients with AKI. 
A methodological, ethical and clinical effort needs to be made 
to improve knowledge and awareness on palliative care in acute 
nephropathic patients.
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